| Hazard Information | Back Directory | [Uses]
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2]. | [in vivo]
Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor[2]. | Animal Model: | Rag1KO-Tg KIR mice injected with tumor cells[2] | | Dosage: | 15 mg/kg | | Administration: | intravenous injection; 15 mg/kg; once | | Result: | Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died. |
| [References]
[1] Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478. DOI:10.1158/1078-0432.CCR-21-2635
[2] Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86. DOI:10.1182/blood-2013-08-519199 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|